Fentanyl Tariff Cuts, Nuclear Weapons Testing and Plastic Eating Bacteria

In partnership with

Anna's Daybreak News

Just facts, you think for yourself

Thursday, 5:12 AM

October 30, 2025

Good morning news friend! Discover today’s defining stories and the future they set in motion. 📰🌟

Click here to read the poll results and comments from our previous edition. Over 5,849 people gave their opinion about Trump’s Asia trip, attacking drug traffickers and more!

Notice: If you’re reading this email in the Gmail app, you will not be able to see both of our health articles at the bottom. 👉 Click here to view the full newsletter online — it’s free and easy to read.

You can wait for the 6 o'clock news, or you can see where the money is moving now.

We just sifted through thousands of new lobbying disclosures—the raw, unfiltered data—to build this week's Washington Heat Map.

The signals are impossible to ignore.

  • Uber is suddenly hiking its D.C. spend by $16.8 million. Their new target? 'Environment' rules.

  • A niche defense contractor just went 100% "all-in" on one single military contract.

  • The entire truck-stop lobby is in a panic over EV credits.

  • Many more …

This isn't opinion. It's a map of where corporate money is placing its bets.

Most investors will get this info a month late. You can get it today.

This is the signal before the noise. See what they're betting on.

Fentanyl Tariff Cuts

President Trump and Chinese leader Xi Jinping met to ease trade tensions, agreeing to cut U.S. tariffs on fentanyl precursor chemicals from 20% to 10%, and China resumed large U.S. soybean purchases.

Both postponed China’s rare-earth mineral export controls for a year; the U.S. held back planned 100% tariffs on Chinese goods. Discussions included semiconductor trade restrictions and a likely deal allowing TikTok to continue U.S. operations. Strategic Taiwan tensions remain, with military drills ongoing and U.S. affirming support. Markets responded positively.

Trump’s Asia trip also included rare-earth agreements with Japan and Southeast Asian nations to reduce China dependence. The deal offers short-term relief but leaves long-term trade and tech conflicts unresolved.

How do you feel about Trumps negotiation with China?

Click to see live results and Comment!

Login or Subscribe to participate in polls.

This free version is ad-supported.

The best investments don't just pay you.

They'll pay your kids. And one day, your grandkids.

That's why I own what I call a "forever stock." It pays income every single month — and it's raised those payouts again and again over the years.

It's the kind of investment you can treat like a family home or a treasured heirloom — something you pass down through generations.

It's not flashy. But it's steady. Reliable. And built to last.

Don’t want to see ads anymore? Click here for an ad-free experience (only $5 per month)

U.S. Nuclear Weapons Testing

President Trump ordered the U.S. to resume nuclear weapons testing following Russia’s tests of a nuclear-powered underwater drone and nuclear-capable cruise missile.

The U.S. halted nuclear tests in 1992 under a longstanding moratorium with Russia and China. Trump pledged to match rivals’ testing "on an equal basis," though it’s unclear whether tests will involve warheads or delivery systems.

This shifts U.S. nuclear policy after more than 30 years of suspension and underscores rising global nuclear competition.

Should the U.S. resume nuclear weapons testing in response to other countries’ actions?

Click to see live results and comment!

Login or Subscribe to participate in polls.

This free version is ad-supported.

Home insurance premiums are up by 9% this year

Home insurance costs continue to climb, with premiums rising over 9% this year and more than 60% in the past five years. However, coverage hasn’t kept pace, leaving many homeowners paying significantly more for less protection. With affordability becoming a growing concern, it’s more important than ever to compare options—check out Money’s handy home insurance tool to find the best fit for you.

Don’t want to see ads anymore? Click here for an ad-free experience (only $5 per month)

Fed Cuts Rates

The Federal Reserve cut interest rates by 0.25 points to 3.75%-4% on October 29, 2025, its second cut this year to address labor market weakness.

The December rate move is uncertain, with market odds for a cut dropping from 90% to 56%. The decision was split 10-2, with calls for a larger cut and some opposition to any cut. The government shutdown, now nearly a month, blocks official September employment data; private reports show a loss of 32,000 jobs and major layoffs at Amazon, Paramount, and UPS.

The Fed will halt quantitative tightening on December 1. Inflation remains at 3%, above the 2% target.

Should the Fed consider a larger rate cut (e.g., 0.5 percentage points) rather than 0.25 points to respond to the labor market slowdown?

Click to see live results and comment!

Login or Subscribe to participate in polls.

Did you know we also write in-depth deep dives? They are long, packed with insights, and have received rave reviews. If you’re up for a detailed, action-packed read, check them out:

OpenAI’s $1 Trillion IPO

OpenAI plans an IPO between late 2026 and early 2027, targeting a valuation up to $1 trillion and raising at least $60 billion. The company has restructured, with the OpenAI Foundation holding 26% of OpenAI Group PBC.

Microsoft owns 27% after a $13 billion investment; total funding stands at $57.9 billion. OpenAI’s revenue run rate may reach $20 billion by 2025, despite ongoing losses and a current $500 billion valuation.

CEO Sam Altman aims to invest trillions into AI infrastructure. The IPO would surpass Saudi Aramco’s $25.6 billion and Alibaba’s $26 billion records, potentially becoming the largest tech IPO and reshaping the AI industry.

Do you believe OpenAI’s $1 trillion IPO valuation is realistic or overly optimistic?

Click to see live results and comment!

Login or Subscribe to participate in polls.

New Hope Against Tuberculosis

CMX410, developed by Texas A&M and Calibr-Skaggs Institute, targets tuberculosis by blocking polyketide synthase 13 (Pks13), essential for the TB bacteria’s cell wall formation.

Tested on 66 Mycobacterium tuberculosis strains, including multidrug-resistant ones, CMX410 was effective against all. It irreversibly binds to Pks13, reducing resistance risk. Early animal tests showed no adverse effects at high doses and minimal harm to beneficial bacteria. The drug can safely combine with existing TB antibiotics, supporting multi-drug regimens.

Developed via click chemistry and funded by the Gates Foundation’s TB Drug Accelerator, CMX410 aims to shorten, simplify, and improve TB treatment. Human trials are needed to confirm safety and efficacy.

The Gates Foundation funds programs like the TB Drug Accelerator. How effective do you believe private philanthropy is compared to government funding in fighting diseases like TB?

Click to see live results and comment!

Login or Subscribe to participate in polls.

Plastic Eating Bacteria

Researchers identified ocean bacteria worldwide that possess a unique M5 motif in PETase enzymes, enabling them to break down PET plastic found in bottles and fabrics.

These bacteria occur in nearly 80% of ocean samples, from surface waters to depths of 2,000 meters. The ability to digest plastic may provide a survival edge in nutrient-poor deep seas. Although this microbial adaptation to pollution is slow, it offers a potential route to developing improved enzymes for industrial plastic recycling.

The M5 motif serves as a blueprint for designing more effective PETases to accelerate plastic breakdown on land, aiding ocean health and future waste management technologies.

Sources: SciTechDaily.

Do you believe microbes evolving to break down plastic represent a hopeful long-term solution to ocean pollution?

Click to see live results and comment!

Login or Subscribe to participate in polls.

A little self-distrust is a healthy thing. The man who is always expecting the worst can't be surprised when the roof finally caves in, which it has a powerful habit of doing.

In a world full of noise and spin, we stay focused on facts. No hype, no hidden motives — just honest reporting.
Become a paid subscriber today and help protect journalism that still believes truth matters.

Baked with love,

Anna Eisenberg ❤️

What did you think of today's edition?

Click to see live results and comment!

Login or Subscribe to participate in polls.